Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

BACKGROUND

Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy.

PATIENTS AND METHODS

Patients with relapsed/refractory disease following ≥1 line of chemotherapy, and whose tumors had progressed following initial disease control (≥12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m(2)/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes.

RESULTS

Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent.

CONCLUSION

Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy.

TRIAL REGISTRATION NUMBER

NCT01085136 (clinicaltrials.gov).

[Treatment of elderly with chronic pain in geriatric care and pain therapy facilities in Germany. Survey results]

BACKGROUND

Even though there are no satisfactory data available on the prevalence of chronic pain in the elderly, it is certainly a common problem in Germany. The goal of this study is to provide information on the treatment of elderly patients with chronic pain in geriatric care and pain therapy facilities in Germany.

METHOD

Throughout Germany geriatric and pain clinics were asked by email about their treatment practice of patients with chronic pain. The questions related to four types of patients sharing the same chronic pain characteristics and comorbidities but differing with respect to cognitive and physical impairment. The questions were divided into the following areas: equipment, staff, patient care, documentation, and cooperation.

RESULTS

Replies from a total of 85 institutions were evaluated. The response rates were approximately 5 % for geriatric units and 10 % for pain units. More patients with chronic pain are treated in geriatrics units than in pain therapy facilities due to larger capacities. Although all four types of patients are treated in both types of facilities, the functionally more competent patients are more common in pain therapy facilities. In geriatrics, the inverse relationship was found. Differences exist in the staff structure and qualification, frequency and refinement of individual and group therapies, assessments used, teamwork, documentation, and cooperation with outpatient care.

CONCLUSION

Due to the differences between geriatric and pain management departments shown in all investigated areas, an exchange between these two cross-sectional subjects could help to improve inpatient, outpatient and intersectoral treatment of elderly patients with chronic pain.